CardioVAI: An automatic implementation of ACMG‐AMP variant interpretation guidelines in the diagnosis of cardiovascular diseases

Variant interpretation for the diagnosis of genetic diseases is a complex process. The American College of Medical Genetics and Genomics, with the Association for Molecular Pathology, have proposed a set of evidence‐based guidelines to support variant pathogenicity assessment and reporting in Mendelian diseases. Cardiovascular disorders are a field of application of these guidelines, but practical implementation is challenging due to the genetic disease heterogeneity and the complexity of information sources that need to be integrated. Decision support systems able to automate variant interpretation in the light of specific disease domains are demanded. We implemented CardioVAI (Cardio Variant Interpreter), an automated system for guidelines based variant classification in cardiovascular‐related genes. Different omics‐resources were integrated to assess pathogenicity of every genomic variant in 72 cardiovascular diseases related genes. We validated our method on benchmark datasets of high‐confident assessed variants, reaching pathogenicity and benignity concordance up to 83 and 97.08%, respectively. We compared CardioVAI to similar methods and analyzed the main differences in terms of guidelines implementation. We finally made available CardioVAI as a web resource (http://cardiovai.engenome.com/) that allows users to further specialize guidelines recommendations.

[1]  R. Bellazzi,et al.  Interplay Between Genetic Substrate, QTc Duration, and Arrhythmia Risk in Patients With Long QT Syndrome. , 2018, Journal of the American College of Cardiology.

[2]  Risha Govind,et al.  CardioClassifier: disease- and gene-specific computational decision support for clinical genome interpretation , 2018, Genetics in Medicine.

[3]  Bruce D. Gelb,et al.  ClinGen’s RASopathy Expert Panel Consensus Methods for Variant Interpretation , 2018, Genetics in Medicine.

[4]  Birgit Funke,et al.  Adaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: recommendations by ClinGen’s Inherited Cardiomyopathy Expert Panel , 2018, Genetics in Medicine.

[5]  M. Hegde,et al.  Diagnostic Yield From 339 Epilepsy Patients Screened on a Clinical Gene Panel. , 2017, Pediatric neurology.

[6]  M. Teles,et al.  Clinical application of ACMG‐AMP guidelines in HNF1A and GCK variants in a cohort of MODY families , 2017, Clinical genetics.

[7]  M. Keramatipour,et al.  A Novel Variant in the PAH Gene Causing Phenylketonuria in an Iranian Pedigree , 2017, Avicenna journal of medical biotechnology.

[8]  Sharon E. Plon,et al.  Evaluation of in silico algorithms for use with ACMG/AMP clinical variant interpretation guidelines , 2017, Genome Biology.

[9]  Quan Li,et al.  InterVar: Clinical Interpretation of Genetic Variants by the 2015 ACMG-AMP Guidelines. , 2017, American journal of human genetics.

[10]  Heather Mason-Suares,et al.  The current state of clinical interpretation of sequence variants. , 2017, Current opinion in genetics & development.

[11]  J. Svendsen,et al.  Integration of 60,000 exomes and ACMG guidelines question the role of Catecholaminergic Polymorphic Ventricular Tachycardia‐associated variants , 2017, Clinical genetics.

[12]  E. Banks,et al.  Analysis of protein-coding genetic variation in 60,706 humans , 2017 .

[13]  Shawn Rynearson,et al.  ClinGen Pathogenicity Calculator: a configurable system for assessing pathogenicity of genetic variants , 2017, Genome Medicine.

[14]  Madhuri Hegde,et al.  Reassessment of Genomic Sequence Variation to Harmonize Interpretation for Personalized Medicine. , 2016, American journal of human genetics.

[15]  Michael J Bamshad,et al.  Guidelines for Large-Scale Sequence-Based Complex Trait Association Studies: Lessons Learned from the NHLBI Exome Sequencing Project. , 2016, American journal of human genetics.

[16]  Matthew S. Lebo,et al.  Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium. , 2016, American journal of human genetics.

[17]  Raymond M. Moore,et al.  Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer. , 2016, American journal of human genetics.

[18]  Linda Jo Bone Jeng,et al.  An openly available online tool for implementing the ACMG/AMP standards and guidelines for the interpretation of sequence variants , 2016, Genetics in Medicine.

[19]  E. Boerwinkle,et al.  dbNSFP v3.0: A One‐Stop Database of Functional Predictions and Annotations for Human Nonsynonymous and Splice‐Site SNVs , 2016, Human mutation.

[20]  Yiping Shen,et al.  Novel and reported APC germline mutations in Chinese patients with familial adenomatous polyposis. , 2016, Gene.

[21]  Ricardo Villamarín-Salomón,et al.  ClinVar: public archive of interpretations of clinically relevant variants , 2015, Nucleic Acids Res..

[22]  R. Weiss,et al.  SCN5A variant that blocks fibroblast growth factor homologous factor regulation causes human arrhythmia , 2015, Proceedings of the National Academy of Sciences.

[23]  Riccardo Bellazzi,et al.  PaPI: pseudo amino acid composition to score human protein-coding variants , 2015, BMC Bioinformatics.

[24]  H. Rehm,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[25]  Xiaohui Xie,et al.  DANN: a deep learning approach for annotating the pathogenicity of genetic variants , 2015, Bioinform..

[26]  Gang Fu,et al.  Disease Ontology 2015 update: an expanded and updated database of human diseases for linking biomedical knowledge through disease data , 2014, Nucleic Acids Res..

[27]  Eric Boerwinkle,et al.  In silico prediction of splice-altering single nucleotide variants in the human genome , 2014, Nucleic acids research.

[28]  D. G. MacArthur,et al.  Guidelines for investigating causality of sequence variants in human disease , 2014, Nature.

[29]  Caroline F. Wright,et al.  Informatics and clinical genome sequencing: opening the black box , 2012, Genetics in Medicine.

[30]  Rick Dale,et al.  Assessing bimodality to detect the presence of a dual cognitive process , 2013, Behavior research methods.

[31]  E. Ashley,et al.  Genetics and Cardiovascular Disease: A Policy Statement From the American Heart Association , 2012, Circulation.

[32]  D. Srivastava,et al.  Genetics of Human Cardiovascular Disease , 2012, Cell.

[33]  R. Hauer,et al.  Distinguishing arrhythmogenic right ventricular cardiomyopathy/dysplasia-associated mutations from background genetic noise. , 2011, Journal of the American College of Cardiology.

[34]  A. Spurdle,et al.  Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results , 2008, Human mutation.

[35]  M. Böhm,et al.  Identification of mutational hot spots in LMNA encoding lamin A/C in patients with familial dilated cardiomyopathy , 2008, Basic Research in Cardiology.

[36]  Michel Haïssaguerre,et al.  Loss-of-Function Mutations in the Cardiac Calcium Channel Underlie a New Clinical Entity Characterized by ST-Segment Elevation, Short QT Intervals, and Sudden Cardiac Death , 2007, Circulation.

[37]  Susana Santos,et al.  Hypertrophic cardiomyopathy in a Portuguese population: mutations in the myosin-binding protein C gene. , 2005, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[38]  Elizabeth M. Smigielski,et al.  dbSNP: the NCBI database of genetic variation , 2001, Nucleic Acids Res..

[39]  J. Hartigan,et al.  The Dip Test of Unimodality , 1985 .